Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms

In patients who have undergone allogeneic hematopoietic cell transplantation (HCT), myeloid mixed donor chimerism (MC) is a risk factor for disease relapse. In contrast, several studies found favorable outcome in patients with lymphoid MC. Thus far, most studies evaluating MC focused on a short-term follow-up period. Here, we report the first case series of long-term survivors with MC. We screened 1,346 patients having undergone HCT for myeloid neoplasms at our center from 1996 to 2016; 443 patients with data on total peripheral blood mononuclear cells (PBMC)/CD4(+)/CD34(+) short tandem repeat (STR) donor chimerism (DC) and follow-up >= 24 months post-HCT were included. We identified 10 patients with long-term MC (PBMC DC <95% at >= 12 months post-HCT). Median follow-up was 11 years. All patients had received combined ex vivo/in vivo T cell-depleted (TCD) peripheral blood stem cells; none experienced >= grade 2 acute graft-versus-host disease (GVHD). The mean total PBMC, CD4(+), and CD34(+) DC of all patients were 95.88%, 85.84%, and 90.15%, respectively. Reduced-intensity conditioning (RIC) was associated with a trend to lower mean total DC. Of note, two patients who experienced relapse had lower CD34(+) DC but higher CD4(+) DC as compared with patients in continuous remission. Bone marrow evaluation revealed increased CD4(+)/FOXP3(+) cells in patients with MC, which might indicate expansion of regulatory T cells (T-regs). Our results support known predictive factors associated with MC such as RIC and TCD, promote the value of CD34(+) MC as a potential predictor of relapse, highlight the potential association of CD4(+) MC with reduced risk of GVHD, and indicate a possible role of T-regs in the maintenance of immune tolerance post-HCT.